- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
Incyte Corp Ltd
+ Add to WatchlistINCY:US
20.3600 USD 1.0500 4.90%
Share
As of 20:10:00 ET on 06/19/2013.
More on INCY
News for Incyte Corp Ltd (INCY)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Start-Ups Fight Patent Wars: Money Moves (03/21)
- Incyte Falls After Patient Develops Infection
- Nasdaq Short Interest by Industries as of Feb. 28
- Largest Nasdaq Short Interest Positions as of Feb. 28
- Nasdaq Short Interest by Industries as of Feb. 15
- Largest Nasdaq Short Interest Positions as of Feb. 15
- Novartis Marrow Drug Fails to Win U.K. Agency Backing
- Nasdaq Short Interest by Industries as of Jan. 31
- Largest Nasdaq Short Interest Positions as of Jan. 31
- Largest Nasdaq Short Interest Changes as of Jan. 31
- Bloomberg Reporter Gets Second Opinion on DNA Test
- My DNA Results Spur Alzheimer’s Anxiety at $12,000 Cost
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Implied Stock-Price Moves for U.S. Companies Reporting Results
- Largest Nasdaq Short Interest Changes as of Feb. 15
- Novartis International AG : Novartis drug Jakavi® improved overall survival of myelofibrosis patients and impacted an Published Jun 16, 2013
- Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis Published Jun 16, 2013
- Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Published Jun 13, 2013
- Jakafi® (ruxolitinib) Prescribing Information Updated with Expanded Dosing Guidance and New Safety Information Published Jun 13, 2013
- Data Presented at 2013 ASCO Offers First Evidence that Long-Term Treatment with Jakafi® (ruxolitinib) May Stabilize or Reverse Published Jun 04, 2013
- Incyte Presents Final Results from a Phase I Trial of INCB024360, a Novel Oral Immunotherapy, at ASCO Published Jun 01, 2013
- Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and Published May 29, 2013
- Novartis International AG : Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung Published May 29, 2013
- Incyte to Present at Upcoming Investor Conferences Published May 22, 2013
- Cancer-Causing Sex Virus Cut in Teen Girls by Vaccines Updated 1 hour ago
- Coronavirus Mystifies Scientists Seeing SARS-Like Spread
- Toxic Toast Concerns Feed Food Enzyme Sales at Novozymes to DSM
- Royalty Pharma Drops Judicial Review Request of Elan Bid
- Tissue Regenix Licenses Technology to U.S. Tissue Bank
- J&J to Buy Aragon Pharmaceuticals for Cancer Candidate
- Elan Investors Approve Buyback to Force Royalty Bid End
- Medtronic, ‘Happy Birthday’: Intellectual Property
- Myriad Gene Patent Ruling Triggers Race for Cancer Tests
- Myriad, Hot Topic, Apple, Del’s: Intellectual Property
- Sullivan & Cromwell, Haynes & Boone: Business of Law
- AbbVie Says It Can Be First With New Hepatitis C Drugs
- Gene Patents Limited by Court in Mixed Ruling for Myriad
- The Supreme Court’s Bad Science on Gene Patents
- Bionor Pharma Surges After HIV Drug Study Progress: Oslo Mover
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page